European Medicine Agency Lists Guillain-Barré Syndrome As Rare Side Effect For JNJ COVID-19 Vaccine

Trending Investment Opportunities

Guillain-Barre syndrome (GBS) will be listed as a very rare side effect of Johnson & Johnson's JNJ COVID-19 Vaccine.
The warning will be included in the product information to raise awareness among healthcare professionals and people taking the vaccine, the EMA said in a statement.
EMA's safety committee, PRAC, looked at 108 cases of GBS reported worldwide as of 30 June, when over 21 million people had received the vaccine.
There was one reported death among these reports.
After assessing the available data, PRAC considered that a causal relationship between COVID-19 Vaccine Janssen and GBS is possible.
EMA confirms that the benefits of COVID-19 Vaccine Janssen continue to outweigh the risks of the vaccine.
Last week, the FDA also listed the rare nerve disorder as a warning to JNJ COVID shot.
According to a study, neutralizing titers induced by JNJ's COVID-19 vaccine decreased 5.4-fold against the Delta plus variant.
Price Action: JNJ shares are up 0.54% at $170.40 during the market session on the last check Thursday.
Related content: Benzinga's Full FDA Calendar.
Photo by Wilfried Pohnke from Pixabay

Momentum61.32

Growth48.45

Quality3.24

Value24.61

Short

Medium

Long